We find the best capital, relationships, and resources and then partner with the best people and organizations in academia, science, spirituality, technology, design, healthcare, and policy. Our goal is to leave no stone unturned and to be willing to explore ways of approaching brain health that may not get the attention they deserve. Only then can we reduce suffering and move humanity forward.
UCLA Depression grand challenge
Since late 2015, we have worked closely in partnership with the UCLA Depression Grand Challenge and the broader University of California ecosystem towards their goal of cutting the burden of depression by 50% by 2050. A core component of this work is a research study of 100,000 people focused on identifying genetic, biological, cognitive, social and environmental factors associated with depression.
Since 2017, we have served on the Board of Trustees with a focus on the Esalen Center for Theory and Research. For over 56 years, Esalen has served as one of the most important research centers for brain health. Where Freud gave us a portrait of the human condition based on pathology, Esalen has looked to all disciplines and practices to uncover human potential and higher health and brain health. From breakthroughs in Gestalt Psychology, to Somatics, to Quantum Physics, and more. Esalen has worked to reconcile the intellectual and experiential; mind and body; science and mysticism; immanence and transcendence; East and West; meditation and action; youthful idealism and time-tested wisdom.
ketamine research foundation
Since 2018, we have served on the board of the Ketamine Research Foundation, a non-profit whose primary missions are research, education and training focusing on ketamine and other transformational medicines. The KRF is focused on five major projects to achieve this mission. First, the Ketamine Data Project focused on providing a comprehensive view of ketamine practices on an independent site by site basis - demonstrating outcomes and efficacy - utilizing the Vanderbilt University Redcap system. Second, KRF is creating an experiential training program for practitioners in KAP - Ketamine Assisted Psychotherapy - in affiliation with the Ketamine Training Institute. Third, The creation of a protocol and a pilot demonstration project for training practitioners in KAP with end-of-life hospice and life-threatening illness patients. Fourth, provide support for selected patients unable to meet costs of treatment on a person-by person basis as funds allow, within a research structure. And fifth, the creation of a complete ketamine data base and library that will serve as a reference for those seeking information and doing research with this medicine.
Since 2017, we have served on the Advisory Board for the Center for Youth Wellness, a non-profit whose vision is every pediatrician in the United States screening for Adverse Childhood Experiences (ACEs) by 2028. CYW’s mission is to improve the health of children and adolescents exposed to Adverse Childhood Experiences (ACEs). Today CYW is a national leader in the effort to advance pediatric medicine, raise public awareness, and transform the way society responds to children exposed to Adverse Childhood Experiences (ACEs) and toxic stress. It all started with our community pediatric clinic and dogged investigation of the question: “What is the connection between childhood adversity and poor health?” CYW now also works at a larger scale: building a national movement, advancing clinical practice, and pushing the science forward.
Johns hopkins medicine
The Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine have served as the most important research center in America since the 1970’s. Dr. Roland Griffiths and his team in 1999 initiated a research program at Johns Hopkins investigating the effects of the classic hallucinogen psilocybin that includes studies of psilocybin-occasioned mystical-type experiences in healthy volunteers, psilocybin-facilitated treatment of psychological distress in cancer patients, psilocybin-facilitated treatment of treatment-resistant depression, psilocybin-facilitated treatment of cigarette smoking cessation, psilocybin effects in beginning and long-term meditators, and psilocybin effects in religious leaders. We have been a financial supporter and advisor to important components of this work. We are happy to report that psilocybin is now in Phase 3 Trials with the FDA for depression.